Unipath and Rohto settle patent litigation:
This article was originally published in Clinica
Unipath's parent company Unilever and Japanese company Rohto Pharmaceutical have settled a two-year patent dispute. The dispute, which related to immunoassays, especially Unipath's Clear series of pregnancy, diagnostic and ovulation testing kits, was heard in the Osaka district court. Rohto will pay undisclosed levels of compensation for its past use of the patent and will pay royalties for manufacturing and selling products based on the patent.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.